Thyroid replacement therapy and heart failure

Circulation

Volumn 122, Issue 4, 2010, Pages 385-393

  Gerdes, Anthony Martin ^a   Iervasi, Giorgio ^b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b Fondazione G Monasterio CNR Regione Toscana   (Italy)

Author keywords

angiogenesis; heart failure; myocardial infarction; remodeling; thyroid hormones

Indexed keywords

DIIODOTHYROPROPIONIC ACID; THYROID HORMONE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFECT; HEART FAILURE; HORMONE ACTION; HORMONE METABOLISM; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; THYROID FUNCTION;

ANIMALS; CARDIOVASCULAR DISEASES; DIIODOTHYRONINES; DISEASE MODELS, ANIMAL; GLOMERULAR FILTRATION RATE; HEART FAILURE; HOMEOSTASIS; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; KIDNEY TUBULES; MUSCLE CELLS; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDES; PROPIONIC ACIDS; THYROID HORMONES; THYROXINE; TRIIODOTHYRONINE; VASODILATION;

EID: 77955130680     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.917922     Document Type: Review

References (97)

1. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501-509.
2. Tang YD, Kuzman JA, Said S, Anderson BE, Wang X, Gerdes AM. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction. Circulation. 2005;112:3122-3130.
3. Olivares EL, Marassi MP, Fortunato RS, da Silva AC, Costa-e-Sousa RH, Araujo IG, Mattos EC, Masuda MO, Mulcahey MA, Huang SA, Bianco AC, Carvalho DP. Thyroid function disturbance and type 3 iodothyronine deiodinase induction after myocardial infarction in rats a time course study. Endocrinology. 2007;148:4786-4792.
4. Wassen FW, Schiel AE, Kuiper GG, Kaptein E, Bakker O, Visser TJ, Simonides WS. Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. Endocrinology. 2002;143:2812-2815.
5. Simonides WS, Mulcahey MA, Redout EM, Muller A, Zuidwijk MJ, Visser TJ, Wassen FW, Crescenzi A, da-Silva WS, Harney J, Engel FB, Obregon MJ, Larsen PR, Bianco AC, Huang SA. Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. J Clin Invest. 2008;118:975-983.
6. Pol CJ, Muller A, Simonides WS. Cardiomyocyte-specific inactivation of thyroid hormone in pathologic ventricular hypertrophy: an adaptative response or part of the problem? Heart Fail Rev. 2010;15:133-142.
7. Pilo A, Iervasi G, Vitek F, Ferdeghini M, Cazzuola F, Bianchi R. Thyroidal and peripheral production of 3,5,3'-triiodothyronine in humans by multicompartmental analysis. Am J Physiol. 1990;258:E715-E726.
8. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23:38-89.
9. Heuer H, Visser TJ. Minireview: pathophysiological importance of thyroid hormone transporters. Endocrinology. 2009;150:1078-1083.
10. Dillmann W. Cardiac hypertrophy and thyroid hormone signaling. Heart Fail Rev. 2010;15:125-132.
11. Katzeff HL, Powell SR, Ojamaa K. Alterations in cardiac contractility and gene expression during low-T3 syndrome: prevention with T3. Am J Physiol. 1997;273:E951-E956.
12. Aber CP, Thompson GS. Factors associated with cardiac enlargement in myxoedema. Br Heart J. 1963;25:421-424.
13. Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid. 2000;10:665-679.
14. Chen WJ, Lin KH, Lee YS. Molecular characterization of myocardial fibrosis during hypothyroidism: evidence for negative regulation of the pro-alpha1(I) collagen gene expression by thyroid hormone receptor. Mol Cell Endocrinol. 2000;162:45-55.
15. Yao J, Eghbali M. Decreased collagen gene expression and absence of fibrosis in thyroid hormone-induced myocardial hypertrophy: response of cardiac fibroblasts to thyroid hormone in vitro. Circ Res. 1992;71: 831-839.
16. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29:76-131.
17. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-238.
18. Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F, L'Abbate A, Pingitore A. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med. 2007;167:1526-1532.
19. Friberg L, Drvota V, Bjelak AH, Eggertsen G, Ahnve S. Association between increased levels of reverse triiodothyronine and mortality after acute myocardial infarction. Am J Med. 2001;111:699-703.
20. Pingitore A, Landi P, Taddei MC, Ripoli A, L'Abbate A, Iervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med. 2005;118:132-136.
21. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, L'Abbate A, Donato L. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation. 2003;107:708-713.
22. Hamilton MA, Stevenson LW, Luu M, Walden JA. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol. 1990;16:91-95.
23. Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med. 2002;137:904-914.
24. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132:270-278.
25. Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J. Subclinical hypothy-roidism is associated with a low-grade inflammation, increased triglyc-eride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf). 2004;61:232-238.
26. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab. 2007;92:1715-1723.
27. Asvold BO, Bjoro T, Nilsen TI, Gunnell D, Vatten LJ. Thyrotropin levels and risk of fatal coronary heart disease: the HUNT study. Arch Intern Med. 2008;168:855-860.
28. Silva-Tinoco R, Castillo-Martinez L, Orea-Tejeda A, Orozco-Gutierrez JJ, Vazquez-Diaz O, Montano-Hernandez P, Flores-Rebollar A, Reza-Albarran A. Developing thyroid disorders is associated with poor prognosis factors in patient with stable chronic heart failure. Int J Cardiol. 2009.
29. Iacoviello M, Guida P, Guastamacchia E, Triggiani V, Forleo C, Catanzaro R, Cicala M, Basile M, Sorrentino S, Favale S. Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. Curr Pharm Des. 2008;14:2686-2692.
30. Vanderpump MP. How should we manage patients with mildly increased serum thyrotrophin concentrations? Clin Endocrinol (Oxf). 2009.
31. Rodondi N, Newman AB, Vittinghoff E, de Rekeneire N, Satterfield S, Harris TB, Bauer DC. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med. 2005; 165:2460-2466.
32. Rodondi N, Bauer DC, Cappola AR, Cornuz J, Robbins J, Fried LP, Ladenson PW, Vittinghoff E, Gottdiener JS, Newman AB. Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure: the Cardiovascular Health Study. J Am Coll Cardiol. 2008;52:1152-1159.
33. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-499.
34. Imaizumi M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M, Usa T, Ashizawa K, Yokoyama N, Maeda R, Nagataki S, Eguchi K. Risk for ischemic heart disease and all-cause mortality in subclinical hypothy-roidism. J Clin Endocrinol Metab. 2004;89:3365-3370.
35. Asvold BO, Vatten LJ, Nilsen TI, Bjoro T. The association between TSH within the reference range and serum lipid concentrations in a population-based study: the HUNT Study. Eur J Endocrinol. 2007;156: 181-186. (Pubitemid 46554512)
36. Coceani M, Iervasi G, Pingitore A, Carpeggiani C, L'Abbate A. Thyroid hormone and coronary artery disease: from clinical correlations to prognostic implications. Clin Cardiol. 2009;32:380-385.
37. Portman MA. Thyroid hormone regulation of heart metabolism. Thyroid. 2008;18:217-225.
38. Bengel FM, Nekolla SG, Ibrahim T, Weniger C, Ziegler SI, Schwaiger M. Effect of thyroid hormones on cardiac function, geometry, and oxidative metabolism assessed noninvasively by positron emission tomography and magnetic resonance imaging. J Clin Endocrinol Metab. 2000;85: 1822-1827.
39. Opasich C, Pacini F, Ambrosino N, Riccardi PG, Febo O, Ferrari R, Cobelli F, Tavazzi L. Sick euthyroid syndrome in patients with moderate-to-severe chronic heart failure. Eur Heart J. 1996;17:1860-1866. (Pubitemid 26413920)
40. Kozdag G, Ural D, Vural A, Agacdiken A, Kahraman G, Sahin T, Ural E, Komsuoglu B. Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyop-athy. Eur J Heart Fail. 2005;7:113-118.
41. Passino C, Pingitore A, Landi P, Fontana M, Zyw L, Clerico A, Emdin M, Iervasi G. Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure. J Card Fail. 2009;15:35-40.
42. Schmidt-Ott UM, Ascheim DD. Thyroid hormone and heart failure. Curr Heart Fail Rep. 2006;3:114-119.
43. Pantos C, Dritsas A, Mourouzis I, Dimopoulos A, Karatasakis G, Atha-nassopoulos G, Mavrogeni S, Manginas A, Cokkinos DV. Thyroid hormone is a critical determinant of myocardial performance in patients with heart failure: potential therapeutic implications. Eur J Endocrinol. 2007;157:515-520.
44. Friberg L, Werner S, Eggertsen G, Ahnve S. Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina? Arch Intern Med. 2002;162:1388-1394.
45. Karlsberg RP, Friscia DA, Aronow WS, Sekhon SS. Deleterious influence of hypothyroidism on evolving myocardial infarction in conscious dogs. J Clin Invest. 1981;67:1024-1034.
46. Ojamaa K, Kenessey A, Shenoy R, Klein I. Thyroid hormone metabolism and cardiac gene expression after acute myocardial infarction in the rat. Am J Physiol Endocrinol Metab. 2000;279:E1319-E1324.
47. Gay RG, Graham S, Aguirre M, Goldman S, Morkin E. Effects of 10-to 12-day treatment with L-thyroxine in rats with myocardial infarction. Am J Physiol. 1988;255:H801-H806.
48. Henderson KK, Danzi S, Paul JT, Leya G, Klein I, Samarel AM. Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ Heart Fail. 2009;2:243-252.
49. Chen YF, Kobayashi S, Chen J, Redetzke RA, Said S, Liang Q, Gerdes AM. Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats. J Mol Cell Cardiol. 2008;44:180-187.
50. Pantos C, Mourouzis I, Saranteas T, Clave G, Ligeret H, Noack-Fraissignes P, Renard PY, Massonneau M, Perimenis P, Spanou D, Kostopanagiotou G, Cokkinos DV. Thyroid hormone improves postis-chaemic recovery of function while limiting apoptosis: a new therapeutic approach to support hemodynamics in the setting of ischaemia-reperfusion? Basic Res Cardiol. 2009;104:69-77.
51. Pantos C, Malliopoulou V, Paizis I, Moraitis P, Mourouzis I, Tzeis S, Karamanoli E, Cokkinos DD, Carageorgiou H, Varonos D, Cokkinos DV. Thyroid hormone and cardioprotection: study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart. Mol Cell Biochem. 2003;242:173-180.
52. Pantos C, Mourouzis I, Cokkinos DV. Rebuilding the post-infarcted myocardium by activating "physiologic" hypertrophic signaling pathways: the thyroid hormone paradigm. Heart Fail Rev. 2010;15: 143-154.
53. Pantos C, Mourouzis I, Markakis K, Dimopoulos A, Xinaris C, Kokkinos AD, Panagiotou M, Cokkinos DV. Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats. Eur J Cardiothorac Surg. 2007;32:333-339.
54. Pantos C, Mourouzis I, Markakis K, Tsagoulis N, Panagiotou M, Cokkinos DV. Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats. Basic Res Cardiol. 2008;103:308-318.
55. Pantos CI, Malliopoulou VA, Mourouzis IS, Karamanoli EP, Paizis IA, Steimberg N, Varonos DD, Cokkinos DV. Long-term thyroxine administration protects the heart in a pattern similar to ischemic preconditioning. Thyroid. 2002;12:325-329.
56. Kuzman JA, Tang Y, Vogelsang KA, Said S, Anderson BE, Morkin E, Gerdes AM. Thyroid hormone analog, diiodothyropropionic acid (DITPA), exerts beneficial effects on chamber and cellular remodeling in cardiomyopathic hamsters. Can J Physiol Pharmacol. 2007;85:311-318.
57. Khalife WI, Tang YD, Kuzman JA, Thomas TA, Anderson BE, Said S, Tille P, Schlenker EH, Gerdes AM. Treatment of subclinical hypothy-roidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;289:H2409-H2415.
58. Liu Y, Redetzke RA, Said S, Pottala JV, de Escobar GM, Gerdes AM. Serum thyroid hormone levels may not accurately reflect thyroid tissue levels and cardiac function in mild hypothyroidism. Am J Physiol Heart Circ Physiol. 2008;294:H2137-H2143.
59. Kinugawa K, Yonekura K, Ribeiro RC, Eto Y, Aoyagi T, Baxter JD, Camacho SA, Bristow MR, Long CS, Simpson PC. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res. 2001;89:591-598.
60. Gerdes AM, Moore JA, Hines JM, Kirkland PA, Bishop SP. Regional differences in myocyte size in normal rat heart. Anat Rec. 1986;215: 420-426.
61. Gerdes AM. The use of isolated myocytes to evaluate myocardial remodeling. Trends Cardiovasc Med. 1992;2:152-155.
62. Gerdes AM. Cardiac myocyte remodeling in hypertrophy and progression to failure. J Card Fail. 2002;8:S264-S268.
63. Zimmer HG, Gerdes AM, Lortet S, Mall G. Changes in heart function and cardiac cell size in rats with chronic myocardial infarction. J Mol Cell Cardiol. 1990;22:1231-1243.
64. Gerdes AM, Kellerman SE, Moore JA, Muffly KE, Clark LC, Reaves PY, Malec KB, McKeown PP, Schocken DD. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation. 1992;86:426-430.
65. Gerdes AM, Onodera T, Wang X, McCune SA. Myocyte remodeling during the progression to failure in rats with hypertension. Hypertension. 1996;28:609-614.
66. Gerdes AM, Moore JA, Hines JM. Regional changes in myocyte size and number in propranolol-treated hyperthyroid rats. Lab Invest. 1987;57: 708-713.
67. Campbell SE, Gerdes AM. Regional changes in myocyte size during the reversal of thyroid-induced cardiac hypertrophy. J Mol Cell Cardiol. 1988;20:379-387.
68. Bai SL, Campbell SE, Moore JA, Morales MC, Gerdes AM. Influence of age, growth, and sex on cardiac myocyte size and number in rats. Anat Rec. 1990;226:207-212.
69. Liu Z, Gerdes AM. Influence of hypothyroidism and the reversal of hypothyroidism on hemodynamics and cell size in the adult rat heart. J Mol Cell Cardiol. 1990;22:1339-1348.
70. Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation. 1998;98:656-662.
71. Thomas TA, Kuzman JA, Anderson BE, Andersen SM, Schlenker EH, Holder MS, Gerdes AM. Thyroid hormones induce unique and potentially beneficial changes in cardiac myocyte shape in hypertensive rats near heart failure. Am J Physiol Heart Circ Physiol. 2005;288:H2118-H2122.
72. Gerdes AM, Kellerman SE, Malec KB, Schocken DD. Transverse shape characteristics of cardiac myocytes from rats and humans. Cardioscience. 1994;5:31-36.
73. Hoshijima M. Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures. Am J Physiol Heart Circ Physiol. 2006;290:H1313-H1325.
74. Yu JG, Russell B. Cardiomyocyte remodeling and sarcomere addition after uniaxial static strain in vitro. J Histochem Cytochem. 2005;53: 839-844.
75. Ervasti JM. Costameres: the Achilles' heel of Herculean muscle. J Biol Chem. 2003;278:13591-13594.
76. Brancaccio M, Fratta L, Notte A, Hirsch E, Poulet R, Guazzone S, De Acetis M, Vecchione C, Marino G, Altruda F, Silengo L, Tarone G, Lembo G. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med. 2003;9:68-75.
77. De Acetis M, Notte A, Accornero F, Selvetella G, Brancaccio M, Vecchione C, Sbroggio M, Collino F, Pacchioni B, Lanfranchi G, Aretini A, Ferretti R, Maffei A, Altruda F, Silengo L, Tarone G, Lembo G. Cardiac overexpression of melusin protects from dilated cardiomyopathy due to long-standing pressure overload. Circ Res. 2005;96:1087-1094.
78. Chaubourt E, Voisin V, Fossier P, Baux G, Israel M, De La Porte S. Muscular nitric oxide synthase (muNOS) and utrophin. J Physiol Paris. 2002;96:43-52.
79. Kruger M, Sachse C, Zimmermann WH, Eschenhagen T, Klede S, Linke WA. Thyroid hormone regulates developmental titin isoform transitions via the phosphatidylinositol-3-kinase/AKT pathway. Circ Res. 2008;102: 439-447.
80. Klemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ, Isom OW, Krieger K. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med. 1995;333:1522-1527.
81. Ranasinghe AM, Quinn DW, Pagano D, Edwards N, Faroqui M, Graham TR, Keogh BE, Mascaro J, Riddington DW, Rooney SJ, Townend JN, Wilson IC, Bonser RS. Glucose-insulin-potassium and tri-iodothyronine individually improve hemodynamic performance and are associated with reduced troponin I release after on-pump coronary artery bypass grafting. Circulation. 2006;114(suppl):I-245-I-250.
82. Portman MA, Fearneyhough C, Ning XH, Duncan BW, Rosenthal GL, Lupinetti FM. Triiodothyronine repletion in infants during cardiopulmo-nary bypass for congenital heart disease. J Thorac Cardiovasc Surg. 2000;120:604-608.
83. Novitzky D. Novel actions of thyroid hormone: the role of triiodothy-ronine in cardiac transplantation. Thyroid. 1996;6:531-536.
84. Hamilton MA, Stevenson LW, Fonarow GC, Steimle A, Goldhaber JI, Child JS, Chopra IJ, Moriguchi JD, Hage A. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol. 1998;81:443-447.
85. Moruzzi P, Doria E, Agostoni PG, Capacchione V, Sganzerla P. Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol. 1994;73:374-378.
86. Iervasi G, Emdin M, Colzani RMP, Placidi S, Sabatino L, Scarlattini M, Formichi B. Beneficial effects of long-term triiodothyronine (T3) infusion in patients with advanced heart failure and low T3 syndrome. In: Kimchi A., ed. Second International Congress on Heart Disease-New Trends in Research, Diagnosis and Treatment. Englewood, NJ: Medimond Medical Publications; 2001:549-553.
87. Ladenson PW, Sherman SI, Baughman KL, Ray PE, Feldman AM. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci USA. 1992;89:5251-5255.
88. Klein I, Danzi S. Thyroid hormone treatment to mend a broken heart. J Clin Endocrinol Metab. 2008;93:1172-1174.
89. Ito K, Kagaya Y, Shimokawa H. Thyroid hormone and chronically unloaded hearts. Vascul Pharmacol. 2010;52:138-141.
90. Khait L, Birla RK. Effect of thyroid hormone on the contractility of self-organized heart muscle. In Vitro Cell Dev Biol Anim. 2008;44: 204-213.
91. Moruzzi P, Doria E, Agostoni PG. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med. 1996;101:461-467.
92. Malik FS, Mehra MR, Uber PA, Park MH, Scott RL, Van Meter CH. Intravenous thyroid hormone supplementation in heart failure with car-diogenic shock. J Card Fail. 1999;5:31-37.
93. Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, L'Abbate A, Mariotti R, Iervasi G. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008;93:1351-1358.
94. Goldman S, McCarren M, Morkin E, Ladenson PW, Edson R, Warren S, Ohm J, Thai H, Churby L, Barnhill J, O'Brien T, Anand I, Warner A, Hattler B, Dunlap M, Erikson J, Shih MC, Lavori P. DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation. 2009;119:3093-3100.
95. Ripoli A, Pingitore A, Favilli B, Bottoni A, Turchi S, Osman NF, De Marchi D, Lombardi M, L'Abbate A, Iervasi G. Does subclinical hypo-thyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study. J Am Coll Cardiol. 2005;45:439-445.
96. Westenberg JJ, van der Geest RJ, Lamb HJ, Versteegh MI, Braun J, Doornbos J, de Roos A, van der Wall EE, Dion RA, Reiber JH, Bax JJ. MRI to evaluate left atrial and ventricular reverse remodeling after restrictive mitral annuloplasty in dilated cardiomyopathy. Circulation. 2005;112(suppl):I-437-I-442.
97. Rajappan K, Bellenger NG, Anderson L, Pennell DJ. The role of cardiovascular magnetic resonance in heart failure. Eur J Heart Fail. 2000;2:241-252.